Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
TN

NASDAQ · TNXP

Tonix Pharmaceuticals Holding Corp.

Healthcare · Biotechnology

$5.17

Up+$0.04 (+0.78%)

Updated Oct 25, 2026, 1:23 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
172.07M
P/E ratio
-2.71
Dividend yield
0.00%
52-week range
$5.01 – $17.00
Volume
754.75K
Avg. volume
886.98K

Price performance · TNXP

TNXP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

TNXP closed at $5.17 after 20 trading sessions, down 47.78% for the selected period.

Last close
$5.17
Period change
-47.78%
Period low
$5.13
Period high
$9.90
Daily close
View OHLC price history
TNXP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$5.09$5.20$5.01$5.17754.75K
Oct 22, 2026$5.37$5.46$5.05$5.13905.74K
Oct 21, 2026$5.85$6.04$5.395$5.43875K
Oct 20, 2026$5.73$6.04$5.545$5.78752.39K
Oct 19, 2026$6.10$6.22$5.61$5.731.34M
Oct 16, 2026$6.46$6.56$6.02$6.04935.46K
Oct 15, 2026$6.50$6.69$6.28$6.422.4M
Oct 14, 2026$6.03$6.72$6.01$6.401.39M
Oct 13, 2026$6.61$6.6798$6.11$6.131.14M
Oct 12, 2026$7.24$7.28$6.635$6.64960.51K
Oct 9, 2026$7.27$7.54$7.09$7.30963.56K
Oct 8, 2026$7.46$7.72$7.16$7.281.09M
Oct 7, 2026$7.70$7.79$7.42$7.55709.35K
Oct 6, 2026$8.15$8.33$7.69$7.6952.54M
Oct 5, 2026$8.82$8.82$8.00$8.071.14M
Oct 2, 2026$9.38$9.56$8.69$8.91803.1K
Oct 1, 2026$9.65$9.69$9.19$9.23477.04K
Sep 30, 2026$9.62$9.92$9.572$9.74318.03K
Sep 29, 2026$9.98$10.08$9.56$9.65394.33K
Sep 28, 2026$9.77$10.05$9.70$9.90342.67K

Latest TNXP news

The latest Smart Investors Daily articles mentioning TNXP.

Stock researchCompany · Overview

TNXP research

Overview

Company profile and research snapshot.

Company profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TNXP recent ratings
DateFirmRatingTarget
Jun 25, 2026Raymond JamesStrong Buy—
May 4, 2026TD CowenBuy—
Mar 20, 2025Noble Capital MarketsOutperform—
Jul 22, 2024Alliance Global PartnersBuy—
Feb 28, 2024Dawson JamesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, held October 26-30, 2026, in Bangkok, Thaila

Yahoo · Oct 15, 2026

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, “Vectored Vaccine Platforms: From Design to Improving

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By